PMID- 33106148
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Linking)
VI  - 16
IP  - 2
DP  - 2021
TI  - Efficacy and Cardiovascular Safety of Thiazolidinediones.
PG  - 233-249
LID - 10.2174/1574886315666201026125530 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is characterized by a progressive beta cell 
      dysfunction in the setting of peripheral insulin resistance. Insulin resistance 
      in subjects with type 2 diabetes and metabolic syndrome is primarily caused by an 
      ectopic fat accumulation in the liver and skeletal muscle. Insulin sensitizers 
      are particularly important in the management of T2DM. Though thiazolidinediones 
      (TZDs) are principally insulin sensitizers, they possess an ability to preserve 
      pancreatic beta-cell function and thereby exhibit durable glycemic control. 
      Cardiovascular outcome trials (CVOTs) have shown that Glucagon-like-peptide 1 
      receptor agonists (GLP-1 RAs) and sodium glucose transporter-2 inhibitors 
      (SGLT2i) have proven cardiovascular safety. In this era of CVOTs, drugs with 
      proven cardiovascular (CV) safety are often preferred in patients with 
      preexisting cardiovascular disease or at risk of cardiovascular disease. In this 
      review, we will describe the three available drugs belonging to the TZD family, 
      with special emphasis on their efficacy and CV safety.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Raveendran, Arkiath Veettil
AU  - Raveendran AV
AD  - Department of Internal Medicine, Badr Al Samaa group of hospitals, Barka, Oman.
FAU - Fernandez, Cornelius James
AU  - Fernandez CJ
AD  - Department of Endocrinology and Metabolism, Pilgrim Hospital, Boston,PE21 9QS, 
      United Kingdom.
FAU - Jacob, Koshy
AU  - Jacob K
AD  - Department of Endocrinology and Metabolism, Eastbourne Hospital, Eastbourne, BN21 
      2UD, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - *Cardiovascular Diseases/chemically induced/diagnosis/epidemiology
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - *Thiazolidinediones
OTO - NOTNLM
OT  - Pioglitazone
OT  - cardiovascular disease
OT  - glycemic control
OT  - heart failure
OT  - insulin resistance
OT  - rosiglitazone
EDAT- 2020/10/28 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/10/27 05:35
PHST- 2020/05/10 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/02 00:00 [accepted]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/10/27 05:35 [entrez]
AID - CDS-EPUB-110902 [pii]
AID - 10.2174/1574886315666201026125530 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2021;16(2):233-249. doi: 10.2174/1574886315666201026125530.